Cold-stored platelet concentrate

Phase 2Biologic

Cold-stored platelet concentrate is one of 3 biologic programs targeting Hematologic Malignancy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematologic MalignancyRecruiting

Hematologic MalignancyPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Hematologic Malignancy

#DrugCompanyPhaseTrials

Claritin

PPerrigo Company

Preclinical

1 2

Cold-stored platelet concentrate

OOttawa Hospital Research Institute

Phase 2

1 3

CD45RA-Depleted DLI

SSt. Jude Children's Research Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Hematologic Malignancy

NCT05820126

Clinical

Trials by Indication[1]

Hematologic Malignancy1 trial

Cold Versus Room Temperature Storage of Platelets for Bleeding in Hematologic Malignancy - a Pilot Trial

Recruiting·OOttawa Hospital Research Institute·Phase 2·NCT05820126·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cold-stored platelet concentrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cold-stored platelet concentrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cold-stored platelet concentrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ottawa Hospital Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: OOttawa Hospital Research Institute

Cold-stored platelet concentrate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Hematologic Malignancy1 trial

References

Drug Info

Quick Facts

Related News